Histone deacetylase (HDAC) inhibitors prevent neural cell death in in vivo models of cerebral ischaemia, brain injury and neurodegenerative disease. One mechanism by which HDAC inhibitors may do this is by suppressing the excessive inflammatory response of chronically activated microglia. However, the molecular mechanisms underlying this antiinflammatory effect and the specific HDAC responsible are not fully understood. Recent data from in vivo rodent studies have shown that inhibition of class I HDACs suppresses neuroinflammation and is neuroprotective. In our study, we have identified that selective HDAC inhibition with inhibitors apicidin, MS-275 or MI-192, or specific knockdown of HDAC1 or 2 using siRNA, suppresses the expression of cytokines interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-a) in BV-2 murine microglia activated with lipopolysaccharide (LPS). Furthermore, we found that in the absence of HDAC1, HDAC2 is up-regulated and these increased levels are compensatory, suggesting that these two HDACs have redundancy in regulating the inflammatory response of microglia. Investigating the possible underlying anti-inflammatory mechanisms suggests an increase in protein expression is not important. Taken together, this study supports the idea that inhibitors selective towards HDAC1 or HDAC2, may be therapeutically useful for targeting neuroinflammation in brain injuries and neurodegenerative disease.
Microglia are the innate immune cells of the brain that are responsible for the excessive and chronic neuroinflammatory response known to contribute to the pathogenesis of brain injury and disease (Block et al. 2007; Glass et al. 2010) . Inhibitors of histone deacetylases (HDACs) reduce the inflammatory response of isolated microglia to stimulants such as lipopolysaccharide (LPS) (Suuronen et al. 2003; Peng et al. 2005; Chen et al. 2007; Faraco et al. 2009; Suh et al. 2010; Kannan et al. 2013) . When delivered in vivo, HDAC inhibitors (HDACi) reduce neuroinflammation, promote neuroprotection and improve functional outcomes in models of cerebral ischaemia Sinn et al. 2007; Xuan et al. 2012; Kim and Chuang 2014) , traumatic brain injury (Zhang et al. 2008; Shein and Shohami 2011) and encephalomyelitis (Camelo et al. 2005; Zhang et al. 2010) . Therapies for treating brain injury and disease are lacking, but these studies highlight a role for HDACs in neuroinflammation and suggest they are appropriate targets to inhibit.
The mechanism by which HDAC inhibition is antiinflammatory is not understood, but we know that HDACs remove acetyl groups from lysine residues on proteins including, histones (Strahl and Allis 2000) , enzymes and transcription factors (Glozak et al. 2005; Yao and Yang 2011) . As a consequence, deacetylation of histones promotes a compact chromatin structure and reduces gene expression, and deacetylation of specific lysine residues on transcription factors can modulate their activity (Gu and Roeder 1997; Boyes et al. 1998) .
The identity of which acetylated proteins are responsible for the anti-inflammatory responses observed when using HDAC inhibitors is unclear. There are 18 mammalian HDAC isoforms (class I HDACs (1, 2, 3 and 8), class II HDACs (4-7, 9 and 10), class III sirtuins (1-7) and the class IV HDAC11) and the majority of studies to date have focused on using non-selective HDAC inhibitors such as suberoylanilide hydroxamic acid (SAHA), trichostatin-A (TSA) and valproic acid (VPA), which inhibit the majority of these isoforms. As a result, we do not know which HDACs modulate the microglial inflammatory response and how inhibition of these leads to the acetylation of specific proteins to reduce neuroinflammation. Recent studies have begun to address these questions and have shown that selective inhibition of Class I HDACs 1, 2 and 3 with the HDAC inhibitor MS-275 (Hu et al. 2003; Simonini et al. 2006; Beckers et al. 2007; Khan et al. 2008) can reduce neuroinflammation in a mouse model of Alzheimer's disease (Zhang and Schluesener 2013) and the inflammatory response of macrophages to the inflammatory stimulant LPS (Jeong et al. 2014) .
In our study, we have used selective HDAC inhibitors and siRNA knockdown to identify HDAC1 and HDAC2 as the key HDACs involved in the neuroinflammatory response of microglia. We show that selective class I HDAC inhibitors and siRNA to specifically knockdown HDAC1 and 2, both suppressed the expression of cytokines in BV-2 murine microglia. Knockdown of HDAC1 alone resulted in a compensatory increase in the levels of HDAC2 and did not suppress cytokine expression, showing these two enzymes have redundancy in the neuroinflammatory response. We show that the HDACi are effective in the absence of new protein synthesis suggesting that the mechanism of HDACi does not involve increased gene expression. This identification suggests that HDAC selective inhibitors may be therapeutically useful for targeting microglia and neuroinflammation in brain injury and disease by modulating the acetylation levels and function of non-histone protein(s).
Materials and methods
Cell culture BV-2 murine microglia [RRID:CVCL_0182, Interlab Cell Line Collection #ATL03001 (Blasi et al. 1990 )] were cultured in Dulbecco's Modified Eagle's Medium high glucose AQmedia TM (Sigma-Aldrich, Poole, Dorset, UK) supplemented with 10% v/v foetal bovine serum (GE Healthcare, Little Chalfont, Buckinghamshire, UK) and 100 U penicillin/100 lg streptomycin (SigmaAldrich). Cells were seeded into six-well plates at either 350 000 or 500 000 cells/well and 24-well plates at 175 000 cells/well. The cells were cultured 24 h before treatment. BV-2 cells were treated with vehicle control, or HDAC inhibitor with or without 500 ng/mL lipopolysaccharide (LPS, Sigma-Aldrich, Poole, Dorset, UK) 1 lM oligomeric Beta-amyloid 1-42 (rPeptide) or 100 ng/mL Interferongamma (IFN-c) and cells harvested after 6 or 24 h. Inhibitors used were: apicidin (Sigma-Aldrich), MI-192 (University of Leeds), MS-275 (Cayman Chemicals, Ann Arbor, Michigan, USA), SAHA (Cayman Chemicals) -all dissolved in dimethylsulfoxide and Valproic acid (VPA, Sigma-Aldrich) dissolved in phosphatebuffered saline (PBS). For pre-treatment experiments, BV-2 cells were treated with vehicle control or appropriate drugs for 24 h before addition of 500 ng/mL LPS for a further 6 h. incubated for 5 min before combining and incubating for a further 20 min at 18°C. Afterwards, 200 lL of this mix was added to the well, followed by incubation at 37°C in a humid atmosphere with 5% CO 2 for 4 h. This was then removed and the cells were cultured in 3 mL Dulbecco's Modified Eagle's Medium high glucose AQmedia TM supplemented with 1% v/v foetal bovine serum and 100 U penicillin/100 lg streptomycin for 24 h followed by a medium change and culture for a further 24 h before treating 500 ng/mL LPS for 6 h.
Cell transfection
Whole cell protein extraction BV-2 cells seeded into six-well plates were washed with 1 mL PBS and scraped into 250 lL ice-cold radioimmunoprecipitation assay Buffer [10 mM Tris-HCL pH 8.0, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% sodium dodecyl sulphate (SDS), 140 mM NaCl, 1 mM phenylmethylsulfonyl fluoride (all from Sigma-Aldrich)], then incubated for 30 min on ice. The lysate was clarified by centrifugation at 13 400 g for 20 min at 4°C and the supernatant containing proteins was collected and the concentration determined using the Bicinchoninic Acid protein assay (SigmaAldrich).
Histone protein extraction
Histone proteins were extracted from BV-2 microglia cultured in sixwell plates. Cells were washed with 1 mL PBS, then scraped into 1 mL ice-cold PBS and pelleted by centrifugation at 400 g for 5 min at 19°C. The cell pellet was resuspended in 400 lL of Triton Lysis Buffer per 1 9 10 7 cells [0.5% v/v Triton X-100, 2 mM phenylmethylsulfonyl fluoride, 0.02% w/v NaN 3 (all from Sigma-Aldrich) and PBS] and incubated on ice for 10 min. Lysed cells were centrifuged at 6600 g for 10 min at 4°C. The pellet was resuspended in half the volume of Triton Lysis Buffer used earlier then centrifuged at 6600 g for 10 min at 4°C. The nuclei pellet was resuspended in 50 lL of 200 mM HCl (Acros Organics, Geel, Belgium) and histone proteins were extracted overnight at 4°C. The samples were centrifuged at 6600 g for 10 min at 4°C and the supernatant containing histone proteins was collected and the protein concentration determined using the Bradford protein assay (SigmaAldrich). followed by washing as before. Membranes were incubated with an enhanced chemiluminescence substrate (Amersham) and exposed to either photographic film, a Fujifilm LAS-3000 imaging system or a cDigit â Scanner (LI-COR, Lincoln, Nebraska, USA). The intensity of each band was quantified and normalized to the b-actin loading control.
Western blotting

RNA extraction, reverse transcription and quantitative PCR (qPCR)
Total RNA was extracted from BV-2 microglia cells using TRI Reagent â (Sigma-Aldrich) as per manufacturer's instructions and resuspended in TE, pH 7.5 and concentration were determined using a NanoDrop 2000c (Thermo Fisher Scientific, Paisley, UK). RNA (2.5 lg) was primed for reverse transcription at 65°C for 5 min with 1.25 lL of Oligo (dT)15 (no reverse transcription) and a no template control were also run.
PCR conditions were: 95°C for 10 min followed by 45 cycles of 95°C for 10 s, 60°C for 15 s and 72°C for 30 s. Relative quantitation of transcript levels was performed using the 2 ÀDDCt method (Livak and Schmittgen, 2001 ) and the house-keeping gene U6.
Enzyme-linked immunosorbant assays (ELISAs)
Cell culture supernatants were taken from BV-2 microglia cells cultured in 24-well plates. The culture medium was removed and centrifuged for 30 s at 16 000 g to pellet any detached cells, then 950 lL was removed for analysis. The concentration of mouse IL-6 protein was determined in triplicate by 96-well plate format ELISAs following Invitrogen's instructions.
Inhibition of protein synthesis
Cells were treated to 500 ng/mL LPS and either vehicle control, 1 lM SAHA or 500 nM apicidin, in the presence or absence of 1 lg/mL cycloheximide for 3 h. Protein synthesis was assessed in the cells using a Click-iT â Plus O-propargyl-puromycin Protein Synthesis
Assay Kit (Molecular Probes, Life Technologies, Grand Island, NY, USA). Briefly, after 2.5 h of drug treatments, Click-iT â O-propargylpuromycin was added directly to each well to give a final concentration of 20 lM. The cells were incubated for a further 30 min at 37°C. The culture medium was removed, the cells washed with PBS, followed by fixation with 100 lL of 4% w/v paraformaldehyde (Sigma-Aldrich) for 15 min at 19°C. The cells were then permeabilized with 100 lL of 0.5% v/v Triton X-100 (Sigma-Aldrich) for 15 min at 19°C, washed twice with PBS and processed for imaging following the manufacturer's instructions. Imaging of labelled cells was carried out using the IncuCyte TM FLR with a 10 9 objective lens. Nine non-overlapping images were taken in phase-contrast and greenfluorescence (excitation wavelength of 450-490 nm) per well. RNA was extracted from parallel treated cultures for qPCR analysis as described above.
Statistics
For qPCR experiments, data are presented either as mean percentage expression of the vehicle control AE SEM or mean percentage expression of LPS +vehicle condition AE SEM. Statistical analysis for each experimental condition versus the vehicle condition was performed using a one-way repeated measures ANOVA followed by the Dunnett's post hoc test (Lew 2007) at the 5% significance level. For ELISA experiments, data are presented as mean protein concentration AE standard deviation (SD). Statistical analysis comparing the absolute absorbance values for each experimental condition versus the vehicle control +LPS condition was performed using a Student's unpaired t-test assuming equal variances at the 5% significance level. For all quantitative data, experiments were performed in triplicate and each experiment was performed at least three times, the 'n' number represents number of experiments performed. No blinding was performed.
Results
Hdac inhibition suppresses cytokine expression in BV-2 microglia Previous studies using isolated murine microglia report that non-selective HDAC inhibitors (SAHA, TSA and VPA) suppress LPS-induced inflammation as measured by a reduction in LPS-induced cytokine expression (tumour necrosis factor-alpha, TNF-a and interleukin-6, IL-6) (Suh et al. 2010; Kannan et al. 2013) . The specific HDAC(s) important in microglia and neuroinflammation are still largely unknown, although identification of the specific HDAC is a requisite for the development of any targeted therapy. We first tested the response of LPS activated BV-2 microglia cells to the classical HDAC inhibitors, SAHA and VPA. BV-2 cells are a widely used model for primary microglia cells showing the same responses across a range of studies [Bocchini et al. 1992; Horvath et al. 2008; Henn et al. 2009; Gresa-Arribas et al. 2012; Stansley et al. 2012) ]. In response to LPS and IFN-c, BV-2 cells show the same elevation of TNF-a, IL-6, COX2, iNOS and NO as primary microglia (Gresa-Arribas et al. 2012) . A transcriptomic analysis of the LPS response of primary microglia and BV-2 cells showed that the gene induction involved the same genes, although the magnitude of change was higher in primary microglia (Henn et al. 2009 ). Like primary microglia, BV-2 cells; are capable of triggering astrocyte activation when co-cultured with them (Horvath et al. 2008; Henn et al. 2009 ), can phagoycytose Ab peptides (He et al. 2011) and show inhibtion of activation in response to IL-10 (GresaArribas et al. 2012). Thus, BV-2 cells show the same responses as primary microglia, providing a suitable model system to study mechanisms underlying these responses with the additional advantage that, unlike primary microglia cultures which are mixed cultures, BV-2 cultures are homogenous. Six hours after stimulation with LPS, oligomeric Abeta or IFN-c, IL-6 mRNA expression was increased (Fig. 1a) . Incubation of BV-2 cells with the HDAC inhibitor SAHA, inhibited the stimulation of IL-6 expression by each of the three stimulants used (Fig. 1a) . BV-2 cells express the Class I HDACs, 1, 2 and 3 with highest levels of HDAC1 and lowest levels of HDAC3 (Fig. 1b and c) . Treatment with the HDAC inhibitors, SAHA and VPA produced an increase in the level of Histone H4 acetylation levels within 1 h, which was stable over a period of 24 h (Fig. 1d) suggesting that these inhibitors provide rapid and stable HDAC inhibition. Activation by LPS in the presence of either 1 lM SAHA or 5 mM of VPA produced a significantly reduced response in IL-6 mRNA expression by 84.1 AE 2.8% and 89.7 AE 1.6%, respectively, and TNF-a mRNA expression by 59.7 AE 3.2% and 77.9 AE 2.5%, respectively, (Fig. 1e) . Furthermore, SAHA significantly suppressed the LPS-induced increase in IL-6 protein secretion by 85.6 AE 2.5% (Fig. 1f) . HDAC treatment did not have a significant effect on IL-6 levels in the absence of LPS stimulation (Fig. 1a and e) and LPS treatment did not have a direct impact on HDAC mRNA levels (Fig. 1g) or protein levels (Fig. 1h) which remained unchanged.
In order to understand the role of specific HDACs in microglia and neuroinflammation, we tested HDAC inhibitors that show some selectivity towards specific HDAC isoforms in vitro. We treated LPS-induced cells with MS-275 [which has reported selectivity for HDAC1 (Bradner, 2010) ], 500 nM apicidin or 1 lM MI-192, [both of which have reported selectivity for HDAC2 and 3 (Khan et al. 2008; Boissinot et al., 2012) ]. Treatment of BV-2 cells with these inhibitors showed a rapid and stable increase in acetylated Histone H4 for apicidin but a gradual increase for MS-275 and MI-192 over a 24-h period (Fig. 2a) . Quantification of histone acetylation levels showed that apicidin produced a similar rate of increase to SAHA, while MS-275 and MI-192 required longer incubation periods to induce high levels of histone acetylation (Fig. 2b) . MS-275 and MI-192 are members of the benzamide class of HDAC inhibitors which have previously been shown to bind HDACs with a slower association rate compared to hydroxamic acid inhibitors such as SAHA (Lauffer et al. 2013) . Consistent with these data, co-treatment of LPS with apicidin was sufficient to reduce the induction of IL-6 and TNF-a expression by 82.7 AE 2.3% and 50.3 AE 4.5% but cotreatment of MS-275 or MI-192 was not, (not shown). Pretreatment of BV-2 cells, to mitigate the slow kinetics of inhibition, with either apicidin, MI-912 or MS-275 for 24 h prior to LPS stimulation significantly reduced the LPSstimulated expression of IL-6 and TNF-a (Fig. 2c) . Together these data suggest that HDAC1 and HDAC2/3 contribute to the inflammatory response in microglia.
Knockdown of HDAC1 or HDAC2 suprresses cytokine expression in BV-2 microglia Although the HDAC inhibitors show selectivity, they are not isoform specific; therefore, we used an siRNA approach to specifically knockdown HDAC1 and HDAC2 expression to determine their involvement in the inflammatory response of microglia. We were able to significantly knockdown HDAC1 protein expression by 62.6 AE 4.5% (Fig. 3a) and HDAC2 protein expression by 68.8 AE 7.7% (Fig. 3a) . Knockdown of HDAC1 resulted in an increased expression of HDAC2 with no change in HDAC3 expression (Fig. 3a) , while knockdown of HDAC2 did not result in any change of expression in HDACs 1 or 3 (Fig. 3a) . Following knockdown, we treated cells to 500 ng/mL LPS for 6 h and assessed the expression of IL-6 and TNF-a mRNA. We found, that cells in which HDAC1 was knocked down, we did not observe any change in the response to LPS compared to control cells (not shown), but cells in which HDAC2 was knocked down showed a reduced induction of IL-6 (by 48.2 AE 13%) and TNF-a (by 22.0 AE 3.6%) expression in response to LPS (Fig. 3b) . To determine if the increase in HDAC2 expression, as a result of HDAC1 knockdown, was acting as a compensatory mechanism, we used siRNA to HDAC1 to knockdown HDAC1 in combination with a titrated amount of HDAC2 siRNA to reduce HDAC2 to levels seen in control cells (Fig. 3, HDAC1+2) . Using this titrated level of HDAC2 siRNA, we were able to reduce HDAC1 levels by 63.5 AE 2.4%, while maintaining the HDAC2 levels seen in control cells (89.7 AE 6.2%, Fig. 3a HDAC1+2) . Expression of HDAC3 was not significantly altered (116 AE 5% of Scr siRNA). Cells in which HDAC1 levels are reduced and HDAC2 levels are unchanged resulted in a reduced response of of IL-6 and TNF-a mRNA to LPS of 34.8 AE 3.0% and 35.7 AE 4.8% respectively (Fig. 3b) .
In summary our data identify HDAC1 and 2 activities as important contributors to the neuroinflammatory response of microglia. HDAC1 and 2 may have the same or independent roles in activation although the observation that they show redundancy in this function with increased HDAC2 levels Quantification of acetylated histone H4 levels, normalized to Histone H3 and expressed relative to acetylation levels at 24 h. (c) BV-2 microglia were pretreated with HDAC inhibitors (HDACi) for 24 h and then stimulated with vehicle or 500 ng/mL lipopolysacchatide (LPS) for 6 h. mRNA expression of interleukin-6 (IL-6) and tumour necrosis factor-a (TNF-a) was determined using qPCR. Relative transcript levels were normalized to the U6 housekeeping gene and expressed as a percentage of the expression in control cells treated with vehicle. Shown are mean AE SEM, n = 3. *p < 0.05, **p < 0.01, ***p < 0.001 compared to LPS-stimulated cells. (Ac-H4) and total histone H3. Representative blots are shown. (e) BV-2 microglia were treated with vehicle or 500 ng/mL LPS AE 1 mM SAHA or 5 mM VPA for 6 h and the mRNA expression of IL-6 and tumour necrosis factor-alpha (TNF-a) was determined using qPCR, normalized to the U6 house-keeping gene and expressed as a percentage of the expression in control cells treated with LPS, shown are mean AE SEM, n = 3 *p < 0.05. (f) BV-2 microglia were treated with 500 ng/mL LPS AE 1 mM SAHA for 24 h and the changes in IL-6 protein secretion was determined by ELISA. Shown are mean protein concentration AE SEM, n = 3 ***p < 0.001. being compensatory for reduced HDAC1 suggests there must be at least some overlap.
HDAC inhibition is effective in reducing the inflammatory response in the absence of new protein synthesis The mechanism by which HDAC inhibitors exert their effects is often assumed to involve increase in gene expression brought about as a result of increased histone acetylation. Incubation of BV-2 cells with these HDAC inhibitors do result in increased histone acetylation (e.g Fig. 1d ) and the association of increased acetylation with increased gene expression was first identified nearly 30 years ago (Hebbes et al. 1988) . However, recent proteomic data have identified in excess of 4000 proteins that are modified by acetylation (Choudhary et al. 2009; Lundby et al. 2012; Liu et al. 2014 ), a number comparable to targets of phosphorylation and suggests that acetylation is involved in many more processes than gene regulation alone. To test a requirement for changes in gene expression for the antiinflammatory action of HDAC inhibition, we blocked new protein synthesis using cycloheximide and tested the effectiveness of HDAC inhibitors to block IL-6 and TNF-a stimulation by LPS. Incubation of BV-2 cells with cycloheximide for 1 or 3 h completely blocked new protein synthesis as measured by O-propargyl-puromycin incorporation and protein synthesis was blocked under all conditions used to quantify gene expression levels (Fig. 4a) . Continued exposure to cycloheximide for 6 h led to cell death (not shown) although 3 h is sufficient time to observe the induction of IL-6 mRNA by LPS stimulation (Fig. 4b , left bar) and cells were still healthy at this time point. The presence of cycloheximide did not affect the induction of IL-6 mRNA expression by LPS (Fig. 4b , compare left two bars) and did not prevent either SAHA or apicidin inhibiting this response (Fig. 4b, right two bars) . Thus, these data indicate that the mechanism by which HDAC inhibition reduces the inflammatory response in microglia is manifest within 3 h and does not require new protein synthesis. Together, this suggests that increased gene expression resulting from enhanced histone acetylation is not important for the ability of HDAC inhibitors to reduce microglia activation and future work should aim to identify the important molecular targets.
Discussion
It has been previously shown that inhibitors of HDACs can reduce the inflammatory response in activated microglia Faraco et al. 2009; Suh et al. 2010; Fig. 3 HDAC1 and HDAC2 are involved in the inflammatory response in microglia. (a) BV-2 microglia were transfected with either scrambled (Scr) siRNA or HDAC1, HDAC2 or HDACs1 and 2 siRNAs. Levels of HDAC1, 2 and 3 and Beta-actin were quantified by immunoblotting. Shown are a representative blots (left) and quantification of protein levels (right) expressed relative to levels in cells treated with Scrambled siRNA. Shown are mean AE SEM, n = 3 *p < 0.05 compared to scrambled siRNA. (b) BV-2 microglia transfected with Scr, HDAC1, HDAC2 or HDAC1 and 2 siRNAs were stimulated with lipopolysacchatide (LPS) and changes in IL-6 and tumour necrosis factor-alpha (TNF-a) mRNA expression was determined using qPCR. Relative transcript levels in each treatment were normalized to the U6 gene and expressed relative to the expression in the Scr siRNA +LPS. Shown are mean AE SEM, n = 3. *p < 0.05. Kannan et al. 2013) and by suppressing microglia activation, show neuroprotective effects following transient ischaemia in vivo Sinn et al. 2007; Xuan et al. 2012; Kim and Chuang 2014) . However, the identity of the important HDACs involved has not been uncovered and the mechanism by which HDAC inhibition is beneficial is yet to be elucidated. Here, we have shown that the function of both HDAC1 and HDAC2 contribute to the inflammatory response in microglia and that in the absence of HDAC1, increased HDAC2 levels compensate suggesting that these two HDACs show redundancy in this function. Furthermore, the effectiveness of HDAC inhibition in the absence of new protein synthesis suggests that the HDACs are promoting the inflammatory response by regulating the acetylation levels of a non-histone protein rather than increasing levels of gene expression as a result of increased histone acetylation.
Microglia are often referred to as the immune cells of the brain and recently, selective inhibition and genetic knockdown of class I HDACs, was shown to reduce the production of cytokines in the inflammatory response of macrophages and treated with vehicle, suberoylanilide hydroxamic acid (SAHA) or apicidin in the presence of cycloheximide. Transcript levels for each treatment were normalized to U6 and data shown are mean mRNA expression levels expressed as a percentage of the expression in LPS +vehicle AE SEM, n = 3, *p < 0.001 versus LPS +vehicle. (Jeong et al. 2014) . In macrophages, knockdown of either HDAC1 or 2 resulted in increased expression of the other and only a combined knockdown of HDACs1, 2 and 3 resulted in reduced inflammatory response to LPS (Jeong et al. 2014) . In T lymphocytes, deletion of HDAC1 resulted in an increase in HDAC2 protein levels but deletion of HDAC2 had no effect on HDAC1 (Dovey et al. 2013) . Here, we show that in microglial cells, HDAC1 is the most highly expressed class I HDAC and knockdown of HDAC1 resulted in a compensatory increase in the levels of HDAC2 (Fig. 3a) . Likewise, we did not observe any compensatory increase in the levels of HDAC1 protein upon knockdown of HDAC2 (Fig. 3a) ; however, this contrasts to observations made using macrophages (Jeong et al. 2014) . The mechanisms resulting in a compensatory increase in one HDAC upon loss of another are not known although HDAC1 does regulate its own promoter (Schuettengruber et al. 2003) and may also repress expression of other HDACs. One prediction of such a model would be that chemical inhibition of HDAC activity would also result in such compensatory increase. However, we did not observe any compensatory changes in HDAC expression in cells treated with HDAC inhibitors (not shown), suggesting that it is not brought about by loss of HDAC enzyme activity but is potentially a mechanism involving the absence of the protein itself. In the absence of HDAC1 in T-lymophocytes, the levels of SIN3 and MTA2 are reduced, which may indicate that incomplete corepressor complexes are turned over quickly (Dovey et al. 2013) . This structural, rather than enzymatic, requirement for HDAC1 may underlie the reason that knockdown of HDAC1, but not inhibition results in a compensatory increase in HDAC2. Additionally, compensatory changes in HDAC protein levels have been observed in the absence of changes in mRNA levels, suggesting that the mechanism involves enhanced translation or protein stability (Jurkin et al. 2011) .
HDAC1 and 2 do not exist in the cell as isolated enzymes but are components of three independent co-repressor complexes; Sin3, NuRD and CoREST [for a review see (Kelly and Cowley 2013) ]. Each co-repressor complex contains two molecules of HDAC, which may consist of two molecules of HDAC1, two molecules of HDAC2 or one of each. Others have observed that upon a loss of HDAC1, HDAC2 can become incorporated into the Sin3, NuRD and CoREST multi-protein complexes in its place (Dovey et al. 2013) . The compensatory effect of HDAC2 in the inflammatory response may be explained by such a mechanism. Following a loss of HDAC1, HDAC2 is up-regulated and this HDAC is incorporated into a specific complex in place of HDAC1. This complex, specifically targets a protein, (which regulates the inflammatory response) for deacetylation. Regardless of the HDAC composition, be it two molecules of HDAC1, HDAC2 or one of each, the specificity for the substrate to be deacetylated comes from the complex itself rather than the HDACs. This hypothesis would suggest that it does not matter which of the two HDAC isoforms is inhibited; an anti-inflammatory effect depends on a reduction in the number and activity of this specific functional multi-protein complex. Similarly, the compensatory effect of HDAC3 when HDAC1 and 2 are both lost in macrophages (Jeong et al. 2014 ) may be explained by HDAC3 being in a specific complex that targets the same substrate as the complex with either HDAC1 or 2. Further research is now needed to investigate these hypotheses and identify the complexes (and composition of them) that when inhibited is responsible for the suppression of pro-inflammatory mediator expression in BV-2 microglia.
What is the important target of HDAC1 and 2 that promotes the inflammatory response? HDAC enzymes were originally characterized by their ability to deacetylate histone proteins, however, these are not their only target and the acetylome may contain in the order of 4000 proteins (Choudhary et al. 2009; Liu et al. 2014) . Additionally, the original idea, that HDAC inhibition leads to increased histone acetylation and increased gene expression is likely too simplistic because as many genes are repressed as are activated upon HDAC inhibition by SAHA (Peart et al. 2005) . The specific HDAC target(s) important for the microglial response has not been unequivocally identified although a number of potential target proteins can be implicated based on a correlation of their acetylation with microglial activation. Perhaps the most studied non-histone protein involved in the inflammatory response and regulated by acetylation is the transcription factor NF-jB . Quiescent NF-jB is restricted to the cytoplasm via its inhibitory binding partner IjB but upon cell stimulation, becomes dissociated from IjB and moves into the nucleus where it activates target gene expression. Initially, it was proposed that deacetylation of NF-jB enhanced its interaction with IjB and removal from the nucleus, however, NF-jB can be acetylated at multiple sites and more recent data suggest that deacetylation at specific residues can result in activation of a subset of NF-jB targets (Rothgiesser et al. 2010) ; thus, inhibition of HDACs may enhance the level of acetylated NF-jB, reducing its activity. In support of this idea, Furumai et al. 2011 showed that inhibition of HDACs in HeLa cells, with TSA, caused a reduction in the recruitment of NF-jB, and RNA polymerase II to the promoter of IL-8 and a reduction in its expression (Furumai et al. 2011) . In macrophages, HDAC1, 2 and 3 can deacetylate MKP-1 (which is a member of the MAPK signalling pathway) regulating its phosphorylation and reducing its activity (Jeong et al. 2014) . MKP-1 is a negative regulator of the inflammatory response not just in macrophages but also in microglia (Eljaschewitsch et al. 2006) making this another attractive candidate for the functional response observed here.
